Published in Clin Exp Metastasis on October 31, 2007
Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One (2011) 2.88
Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. Cancer Res (2009) 1.42
Androgen receptor promotes ligand-independent prostate cancer progression through c-Myc upregulation. PLoS One (2013) 1.29
Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer. Nat Med (2016) 1.22
Eph receptors and ephrin signaling pathways: a role in bone homeostasis. Int J Med Sci (2008) 1.17
Laminin-332 is a substrate for hepsin, a protease associated with prostate cancer progression. J Biol Chem (2008) 1.14
Genome-wide testing of putative functional exonic variants in relationship with breast and prostate cancer risk in a multiethnic population. PLoS Genet (2013) 1.10
Tumor angiogenesis: insights and innovations. J Oncol (2010) 1.04
EphA receptor signaling--complexity and emerging themes. Semin Cell Dev Biol (2011) 1.00
Advances in osteoclast biology reveal potential new drug targets and new roles for osteoclasts. J Bone Miner Res (2013) 0.99
Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells. Anticancer Drugs (2010) 0.97
The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells. Prostate (2010) 0.96
A novel four-color fluorescence in situ hybridization assay for the detection of TMPRSS2 and ERG rearrangements in prostate cancer. Cancer Genet (2013) 0.91
Inhibition of angiopoietin-2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability. Prostate (2010) 0.89
Understanding and targeting osteoclastic activity in prostate cancer bone metastases. Curr Mol Med (2013) 0.87
A three-marker FISH panel detects more genetic aberrations of AR, PTEN and TMPRSS2/ERG in castration-resistant or metastatic prostate cancers than in primary prostate tumors. PLoS One (2013) 0.86
Nonlinear model-based estimates of IC(50) for studies involving continuous therapeutic dose-response data. Contemp Clin Trials (2008) 0.85
Prostate tumor cell plasticity: a consequence of the microenvironment. Adv Exp Med Biol (2011) 0.84
Gastric tumour-derived ANGPT2 regulation by DARPP-32 promotes angiogenesis. Gut (2015) 0.81
Novel methods to identify biologically relevant genes for leukemia and prostate cancer from gene expression profiles. BMC Genomics (2010) 0.81
Fibulin-1 is epigenetically down-regulated and related with bladder cancer recurrence. BMC Cancer (2014) 0.79
Visceral metastases and prostate cancer treatment: 'die hard,' 'tough neighborhoods,' or 'evil humors'? Oncology (Williston Park) (2014) 0.78
Fibulin-1 is downregulated through promoter hypermethylation in colorectal cancer: a CONSORT study. Medicine (Baltimore) (2015) 0.77
Gene expression analysis of bone metastasis and circulating tumor cells from metastatic castrate-resistant prostate cancer patients. J Transl Med (2016) 0.77
Microenvironmental regulation of tumour angiogenesis. Nat Rev Cancer (2017) 0.76
The role of the cell-cell interactions in cancer progression. J Cell Mol Med (2015) 0.75
Tumor Vascular Morphology Undergoes Dramatic Changes during Outgrowth of B16 Melanoma While Proangiogenic Gene Expression Remains Unchanged. ISRN Oncol (2011) 0.75
The up-regulation of Myb may help mediate EGCG inhibition effect on mouse lung adenocarcinoma. Hum Genomics (2016) 0.75
MBDDiff: an R package designed specifically for processing MBDcap-seq datasets. BMC Genomics (2016) 0.75
High-Resolution Genomic Profiling of Disseminated Tumor Cells in Prostate Cancer. J Mol Diagn (2015) 0.75
Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A (2001) 132.88
Vascular-specific growth factors and blood vessel formation. Nature (2000) 14.42
Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol (2000) 7.94
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88
Imaging of angiogenesis: from microscope to clinic. Nat Med (2003) 5.51
Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res (2001) 3.45
Fibrinogen and fibrin. Adv Protein Chem (2005) 3.45
Cellular abnormalities of blood vessels as targets in cancer. Curr Opin Genet Dev (2005) 3.38
Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol (2003) 3.17
Metastases from carcinoma of mammary gland: an autopsy study. J Surg Oncol (1979) 2.06
Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate (1999) 1.92
Hepsin promotes prostate cancer progression and metastasis. Cancer Cell (2004) 1.89
Angiogenesis and prostate cancer: in vivo and in vitro expression of angiogenesis factors by prostate cancer cells. Urology (1998) 1.73
Transforming growth factor beta1 is associated with angiogenesis, metastasis, and poor clinical outcome in prostate cancer. Prostate (1998) 1.58
Perinatal lethality and endothelial cell abnormalities in several vessel compartments of fibulin-1-deficient mice. Mol Cell Biol (2001) 1.51
PEDB: the Prostate Expression Database. Nucleic Acids Res (1999) 1.42
Human osteocalcin and bone sialoprotein mediating osteomimicry of prostate cancer cells: role of cAMP-dependent protein kinase A signaling pathway. Cancer Res (2005) 1.41
Vascular invasion and herniation by hepatocellular carcinoma in cirrhosis: A wolf in sheep's clothing? Arch Pathol Lab Med (2005) 1.39
Platelet-derived growth factor D is activated by urokinase plasminogen activator in prostate carcinoma cells. Mol Cell Biol (2005) 1.35
Identification and cDNA cloning of a novel RNA-binding protein that interacts with the cyclic nucleotide-responsive sequence in the Type-1 plasminogen activator inhibitor mRNA. J Biol Chem (2000) 1.33
Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate (2002) 1.30
Mechanisms, hypotheses and questions regarding prostate cancer micrometastases to bone. Cancer Metastasis Rev (1999) 1.30
Differential expression of angiopoietin-1 and angiopoietin-2 in colon carcinoma. A possible mechanism for the initiation of angiogenesis. Cancer (2001) 1.27
Ephrin-A1 facilitates mammary tumor metastasis through an angiogenesis-dependent mechanism mediated by EphA receptor and vascular endothelial growth factor in mice. Cancer Res (2006) 1.27
The interaction of fibulin-1 with fibrinogen. A potential role in hemostasis and thrombosis. J Biol Chem (1995) 1.25
Administration of zoledronic acid enhances the effects of docetaxel on growth of prostate cancer in the bone environment. BMC Cancer (2006) 1.23
Angiopoietin 2 expression is related to histological grade, vascular density, metastases, and outcome in prostate cancer. Prostate (2005) 1.18
The involvement of endothelial progenitor cells in tumor angiogenesis. J Cell Mol Med (2004) 1.17
Differential expression of osteopontin and bone sialoprotein in bone metastasis of breast and prostate carcinoma. Clin Exp Metastasis (2003) 1.13
Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer. Hum Pathol (2006) 1.12
Expression of urokinase plasminogen activator, its receptor and type-1 inhibitor in malignant and benign prostate tissue. Int J Cancer (2005) 1.12
Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology. Am J Pathol (2000) 1.04
Pro-urokinase-type plasminogen activator is a substrate for hepsin. J Biol Chem (2006) 1.03
Cellular interactions in the tropism of prostate cancer to bone. Int J Cancer (2004) 1.00
The urokinase-type plasminogen activator system in prostate cancer metastasis. Cancer Metastasis Rev (2001) 0.99
Osteoblast-derived TGF-beta1 modulates matrix degrading protease expression and activity in prostate cancer cells. Int J Cancer (2000) 0.97
Future treatment of bone metastases. Clin Cancer Res (2006) 0.96
Investigation into the mechanism of the loss of laminin 5 (alpha3beta3gamma2) expression in prostate cancer. Am J Pathol (2001) 0.94
Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers. J Bone Miner Res (2000) 0.94
Histological, immunophenotypic and histomorphometric characterization of prostate cancer bone metastases. Cancer Treat Res (2004) 0.93
Fibulin-1 mediates platelet adhesion via a bridge of fibrinogen. Blood (1996) 0.92
Association of prostate-specific membrane antigen with caveolin-1 and its caveolae-dependent internalization in microvascular endothelial cells: implications for targeting to tumor vasculature. Microvasc Res (2006) 0.85
Posttranscriptional regulation of PAI-1 gene expression. Thromb Haemost (2003) 0.84
Pain management in patients with advanced prostate cancer. Oncology (Williston Park) (1999) 0.83
Androgen receptor stimulates bone sialoprotein (BSP) gene transcription via cAMP response element and activator protein 1/glucocorticoid response elements. J Cell Biochem (2007) 0.80
Fibrin formation on vessel walls in hyperplastic and malignant prostate tissue. Cancer (1991) 0.79
Transforming growth factor beta1 stimulates urokinase plasminogen activator system on prostate cancer cells. Int J Biol Markers (2003) 0.78
Expression of tissue factor is associated with clinical features and angiogenesis in prostate cancer. Anticancer Res (2003) 0.77
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
Senescence-associated secretory phenotypes reveal cell-nonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLoS Biol (2008) 11.43
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 10.66
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med (2012) 8.64
Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell (2003) 8.11
MicroRNA expression profiling in prostate cancer. Cancer Res (2007) 8.04
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res (2009) 7.11
Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol (2007) 6.73
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res (2008) 6.33
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med (2013) 6.17
NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw (2010) 5.98
Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer. Cancer Res (2007) 5.97
Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant. J Clin Invest (2010) 5.77
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol (2006) 5.72
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer. Cancer Res (2012) 4.67
Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res (2011) 4.65
A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A (2008) 3.83
EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science (2012) 3.74
Absolute quantification by droplet digital PCR versus analog real-time PCR. Nat Methods (2013) 3.63
Monoclonal antibody targeting of N-cadherin inhibits prostate cancer growth, metastasis and castration resistance. Nat Med (2010) 3.61
Exome sequencing identifies a spectrum of mutation frequencies in advanced and lethal prostate cancers. Proc Natl Acad Sci U S A (2011) 3.54
Minimum information specification for in situ hybridization and immunohistochemistry experiments (MISFISHIE). Nat Biotechnol (2008) 3.43
Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA (2006) 3.32
Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol (2009) 3.24
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol (2005) 3.22
Treatment-induced damage to the tumor microenvironment promotes prostate cancer therapy resistance through WNT16B. Nat Med (2012) 3.21
Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol (2003) 3.17
Human cancers express a mutator phenotype. Proc Natl Acad Sci U S A (2006) 3.11
The retinoblastoma tumor suppressor controls androgen signaling and human prostate cancer progression. J Clin Invest (2010) 3.09
The gene expression program of prostate fibroblast senescence modulates neoplastic epithelial cell proliferation through paracrine mechanisms. Cancer Res (2006) 3.07
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol (2007) 3.05
A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell (2013) 2.94
A targeted proteomics-based pipeline for verification of biomarkers in plasma. Nat Biotechnol (2011) 2.91
A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci U S A (2006) 2.89
Androgen receptor variants occur frequently in castration resistant prostate cancer metastases. PLoS One (2011) 2.88
Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine-specific demethylase 1. Cancer Cell (2011) 2.86
Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res (2011) 2.81
Activated mammalian target of rapamycin pathway in the pathogenesis of tuberous sclerosis complex renal tumors. Cancer Res (2002) 2.81
Urinary TMPRSS2:ERG and PCA3 in an active surveillance cohort: results from a baseline analysis in the Canary Prostate Active Surveillance Study. Clin Cancer Res (2013) 2.70
Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res (2006) 2.69
Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab (2006) 2.57
Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis. J Clin Oncol (2006) 2.56
The value of sharing treatment decision making with patients: expecting too much? JAMA (2013) 2.48
Guidelines for the development and incorporation of biomarker studies in early clinical trials of novel agents. Clin Cancer Res (2010) 2.44
Prostate cancer, version 2.2014. J Natl Compr Canc Netw (2014) 2.40
NCCN clinical practice guidelines in oncology: kidney cancer. J Natl Compr Canc Netw (2009) 2.40
NCCN clinical practice guidelines in oncology: prostate cancer early detection. J Natl Compr Canc Netw (2010) 2.31
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol (2013) 2.29
LuCaP 35: a new model of prostate cancer progression to androgen independence. Prostate (2003) 2.28
Tumor-induced anorexia and weight loss are mediated by the TGF-beta superfamily cytokine MIC-1. Nat Med (2007) 2.20
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol (2014) 2.19
TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res (2008) 2.16
Rapid induction of androgen receptor splice variants by androgen deprivation in prostate cancer. Clin Cancer Res (2014) 2.15
Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res (2003) 2.14
PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res (2011) 2.10
Frequent somatic mutations of the transcription factor ATBF1 in human prostate cancer. Nat Genet (2005) 2.08
Oncosome formation in prostate cancer: association with a region of frequent chromosomal deletion in metastatic disease. Cancer Res (2009) 2.07
Prostate cancer early detection. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2007) 2.06
Eligibility and outcomes reporting guidelines for clinical trials for patients in the state of a rising prostate-specific antigen: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol (2004) 2.04
FOXO1A is a candidate for the 13q14 tumor suppressor gene inhibiting androgen receptor signaling in prostate cancer. Cancer Res (2006) 2.03
Supervised normalization of microarrays. Bioinformatics (2010) 2.00
Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2013) 1.95
Correlation of mRNA and protein levels: cell type-specific gene expression of cluster designation antigens in the prostate. BMC Genomics (2008) 1.95
Detection and isolation of prostate cancer cells from peripheral blood and bone marrow. Urology (2003) 1.94